Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Ustianowski, Andrew; Arends, Joop E.

doi:10.1007/s40121-015-0070-1

Cited by 37 publications

(25 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Erlotinib and genistein both inhibit the Endothelial Growth Factor Receptor (EGFR), and the EGFR gene expression profile showed overexpression in 38.2% of tumour samples from an independent cohort of 63 ccRCC patients 12 . The nucleotide reverse transcriptase inhibitor tenofovir is associated with nephrotoxicity due to accumulation in the proximal tubules 13 , which ccRCC is thought to originate from. The similarity in gene expression between ccRCC and proximal tubules cells has been noted before 14 , and therefore it seems plausible they share the same toxicity as well.…”

Section: Discussionmentioning

confidence: 99%

Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression

Koudijs

Scheltinga

Böhringer

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Reversal of cancer gene expression is predictive of therapeutic potential and can be used to find new indications for existing drugs (drug repositioning). Gene expression reversal potential is currently calculated, in almost all studies, by pre-aggregating all tumour samples into a single group signature or a limited number of molecular subtype signatures. Here, we investigate whether drug repositioning based on individual tumour sample gene expression signatures outperforms the use of tumour group and subtype signatures. The tumour signatures were created using 534 tumour samples and 72 matched normal samples from 530 clear cell renal cell carcinoma (ccRCC) patients. More than 20,000 drug signatures were extracted from the CMAP and LINCS databases. We show that negative enrichment of individual tumour samples correlated (Spearman’s rho = 0.15) much better with the amount of differentially expressed genes in drug signatures than with the tumour group signature (Rho = 0.08) and the 4 tumour subtype signatures (Rho 0.036-0.11). Targeted drugs used against ccRCC, such as sirolimus and temsirolimus, which could not be identified with the pre-aggregated tumour signatures could be recovered using individual sample analysis. Thus, drug repositioning can be personalized by taking into account the gene expression profile of the individual’s tumour sample.

show abstract

Section: Discussionmentioning

confidence: 99%

Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression

Koudijs

Scheltinga

Böhringer

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Some reports have also shown that HAART is associated with decreased prevalence of renal disease and amelioration of progression in the general population and in HIV infected patients with chronic renal disease [45][46][47]. Some degrees of adverse drug reactions have been reported after the use of HAART in HIV infected subjects including the use of second-line regimen [48] However, studies have reported cases of kidney disease after the introduction of tenofovir-containing HAART [9,49].…”

Section: Discussionmentioning

confidence: 99%

“…Presentation of nephrotoxicity can appear as Fanconi syndrome, acute kidney injury, or decline of GFR. Nephrotoxicity may be due to proximal tubules accumulation of tenofovir disoproxil leading to elevated serum concentrations [9]. Recent reports have linked HAART regimens that contain tenofovir to a mild, time-dependent elevation in the serum creatinine level and a decrease in the glomerular filtration rate [10].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Kidney Function, Estimated Glomerular Filtration Rate and Body Mass Index in Hiv Seropositive Subjects on Antiretroviral Therapy in Nnewi

Onwubuya

Ukibe

Kalu

et al. 2018

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: Antiretroviral therapy (ART) is anticipated to result in an increase in long-term survival in human immunodeficiency virus (HIV) infected individuals, but may present with the development of associated complications including kidney damage. The present study aimed at assessing the kidney function estimated glomerular filtration (eGFR) rate and body mass index (BMI) of HIV seropositive subjects with or without HAART at Nnewi, Nigeria. Methods:A total of 90 subjects were recruited comprising of 30 HIV-seropositive on highly antiretroviral therapy (HAART), 30 HIV-seropositive drug naive, and 30 HIV-seronegative (control subjects). Anthropometric parameters of the subjects were assessed using a well-structured questionnaire. Five millilitres of blood sample was collected from the patients and used for the estimation of urea, creatinine, uric acid, serum total protein and cluster of differentiation (CD4) T-cell counts using diacetyl monoxime method, Jaffe-slot method, Caraway phosphotungstic acid method, refractometry and flow cytometric method respectively.

show abstract

“…[17] It should also be taken into consideration that most data on TDF ADRs are from controlled trials in populations that are genetically different from much of SA's student population. Furthermore, many individuals in resource-limited settings use a dual system of healthcare, traditional and conventional.…”

Section: What About the Cost?mentioning

confidence: 99%

Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises

Montjane¹,

Dlamini²,

Dandara³

2018

S Afr Med J

View full text Add to dashboard Cite

Antiretroviral therapy (ART) has fundamentally altered the natural history of HIV/AIDS, sharply reducing HIV-related morbidity and prolonging longevity. However, there seems to be a resurgence in HIV infection rates in some parts of the world that has prompted consideration of pre-exposure prophylaxis (pre-EP) and vaccination. Despite their good viral suppression profiles, most drugs used as part of ART also have unwanted adverse drug reactions/effects (ADRs). In this article we acknowledge the utility of pre-EP in combating HIV transmission, but we also highlight the need to prepare for management of other unexpected outcomes such as ADRs and viral resistance, to ensure the success of the programme.

show abstract

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Cited by 37 publications

References 88 publications

Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression

Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression

Assessment of Kidney Function, Estimated Glomerular Filtration Rate and Body Mass Index in Hiv Seropositive Subjects on Antiretroviral Therapy in Nnewi

Truvada (emtricitabine/tenofovir) pre-exposure prophylaxis roll-out among South African university students: Lots of positives, but let us keep an eye on possible surprises

Contact Info

Product

Resources

About